Status:
UNKNOWN
Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Disease (COVID-19) in the Oncology Outpatient Setting
Lead Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Conditions:
Cancer
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
The COVIDOUT study will prospectively investigate the serological immunity of outpatient cancer patients to evaluate the prevalence of previous severe acute respiratory syndrome coronavirus 2 (SARS-Co...
Detailed Description
In this prospective observational study all cancer patients who are regularly treated in the Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf (UKE) will be included in the...
Eligibility Criteria
Inclusion
- Known diagnosis of cancer
- Active disease or (in case of cure) last systemic therapy \<12 months
- Signed informed consent
Exclusion
- Refusal of participation
Key Trial Info
Start Date :
December 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04779346
Start Date
December 21 2020
End Date
December 31 2022
Last Update
March 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany, 20246